Page
%P
21 Result(s)
within
Praveen Thokala
Medicine & Public Health
English
Pharmacoeconomics and Health Outcomes
-
Article
Open AccessIssues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review
There are significant challenges when obtaining clinical and economic evidence for health technology assessments of rare diseases. Many of them have been highlighted in previous systematic reviews but they hav...
-
Article
Open AccessCost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis
Chronic kidney disease-associated pruritus (CKD-aP) is associated with an increased risk of depression, poor sleep and reduced health-related quality of life. Two phase III studies (KALM-1 and KALM-2) of difel...
-
Article
Living Health Technology Assessment: Issues, Challenges and Opportunities
Health technology assessments (HTAs) are typically performed as one-off evaluations and can potentially become out-of-date due to the availability of new data, new comparators, or other factors. Recently, livi...
-
Article
Open AccessENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients
Improved multiple sclerosis (MS) diagnosis and increased availability of intravenous disease-modifying treatments can lead to overburdening of infusion centres. This study was focused on develo** a decision-...
-
Article
Open AccessCost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
Patients with infantile-onset spinal muscular atrophy (SMA), a rare, genetic neuromuscular disease, do not achieve key motor function milestones (e.g., sitting) and have short life expectancy in the absence of...
-
Article
Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review
The objectives of this systematic review were to identify studies using Multi-Criteria Decision Analysis (MCDA) software tools to support health prioritisation processes and describe the technical capabilities...
-
Article
Transparency in Health Economic Modeling: Options, Issues and Potential Solutions
Economic models are increasingly being used by health economists to assess the value of health technologies and inform healthcare decision making. However, most published economic models represent a kind of bl...
-
Article
Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
As part of its Single Technology Appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of ibrutinib (Janssen) to submit evidence on the clinical and ...
-
Article
Open AccessStakeholder involvement in Multi-Criteria Decision Analysis
This brief perspective highlights the importance of decision maker buy-in and ownership through stakeholder engagement in the co-construction of the multi-criteria decision analysis (MCDA) model. A brief histo...
-
Article
Open AccessIncorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings
Multicriteria decision analysis (MCDA) has the potential to bring more structure and transparency to health technology assessment (HTA). The objective of this paper is to highlight key methodological and pract...
-
Article
Cost-Effectiveness Thresholds: the Past, the Present and the Future
Cost-effectiveness (CE) thresholds are being discussed more frequently and there have been many new developments in this area; however, there is a lack of understanding about what thresholds mean and their imp...
-
Article
Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer of pertuzumab (Perjeta®; Roche Products Limited) to submit evidence of its clinic...
-
Article
Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment
The objective of this article was to conduct a systematic review of published research on the use of discrete event simulation (DES) for resource modelling (RM) in health technology assessment (HTA). RM is bro...
-
Article
Simulation Modelling in Healthcare: An Umbrella Review of Systematic Literature Reviews
Numerous studies examine simulation modelling in healthcare. These studies present a bewildering array of simulation techniques and applications, making it challenging to characterise the literature.
-
Book
-
Chapter
Introduction
Multi-criteria decision analysis (MCDA) has the potential to support better healthcare decision making. But a number of challenges need to be overcome before it can achieve its potential. These are both techni...
-
Chapter
MCDA for Resource Allocation at a Local Level: An Application in the UK
Resource allocation at a local level involves making difficult decisions about investment and, particularly in a time of economic stringency, about disinvestment. These complex decisions are influenced by a nu...
-
Chapter
Incorporating Preferences and Priorities into MCDA: Selecting an Appropriate Scoring and Weighting Technique
A key component of many multi-criteria decision analyses (MCDAs) is the elicitation of stakeholder preferences in the form or scores and weights. A challenge to the MCDA practitioner is that there is little gu...
-
Article
Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of olaparib (AstraZeneca) to submit evidence on the clinical and cost e...
-
Article
Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective
The National Institute for Health and Care Excellence (NICE) invited Dendreon, the company manufacturing sipuleucel-T, to submit evidence for the clinical and cost effectiveness of sipuleucel-T for asymptomati...
